title: Low-dose rosiglitazone plus metformin reduces risk of incident type 2 diabetes compared with placebo in people with impaired glucose tolerance.
authors.affiliation: ICM-Diabetes, The Medical School, Newcastle University, Newcastle upon Tyne, UK. philip.home@ncl.ac.uk
authors.forename: Philip D
authors.initials: PD
authors.lastname: Home